Results · Apr-Jun 2026
Cohance Lifesciences Q1 FY27 results
Sales fell 23% to ₹422 crore from ₹549 crore in Apr-Jun 2025.
Operating profit fell 99% to ₹1.2 crore, an operating margin of 0.3% (down 20.1 points from a year ago).
Net profit turned into a loss of ₹45.2 crore, from a profit of ₹46.4 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −32%, swings to a loss.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 422.3 | 549.3 | −23% |
| Operating profit (EBITDA) | 1.2 | 112.0 | −99% |
| Operating margin | 0.3% | 20.4% | −20.1 pts |
| Net profit | -45.2 | 46.4 | swings to a loss |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.